Skip to content

Achieve Life Sciences ACHV Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation

Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation at other companies

EAT
Brinker InternationalEAT
$42.1M
CBIZ logo
CBIZCBZ
-$41.01M-8.3%
UMH
UMH PropertiesUMH
-$34.96M+43.9%
Equitable Holdings logo
Equitable HoldingsEQH
-$2.56B-313%
ePlus logo
ePlusPLUS
$84.48M-38.0%
Healthcare Services Group logo
Healthcare Services GroupHCSG
$5.5M+29.5%

Other financials

Income statement

See full
Net income-$10.2M+20.7%
EPS (diluted)-$0.19+48.6%

Balance sheet

See full
Cash & equivalents$28.1M+116%
Total debt$5.6M+332%
Total equity$10.7M+3.9%
Total assets$33.1M+21.0%

Cash flow

See full
Operating cash flow-$6.9M+37.5%
CapEx$750.0
Free cash flow-$12.4M

Valuation

See full
Market cap$585.16M+404%
Enterprise value$562.71M+439%

Returns & leverage

See full
Return on equity-496.1%-906pp
Debt / equity0.5×+0.4×
Current ratio2.6×-0.9×

Where this comes from

Reported directly by Achieve Life Sciences in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The official record: Achieve Life Sciences’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Achieve Life Sciences's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Achieve Life Sciences's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation?
Achieve Life Sciences (ACHV) reported cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation of $7.36M in Q1 2026.
How has Achieve Life Sciences's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation changed year-over-year?
Achieve Life Sciences's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation increased by 2700.0% year-over-year, from $263K to $7.36M.
What does cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation mean?
The net change in the total balance of cash, cash equivalents, and restricted cash over a specific reporting period, inclusive of exchange rate impacts. This metric provides a comprehensive view of the company's liquidity movement. It serves as a primary indicator of the firm's ability to fund operations and meet short-term obligations.